Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy

Launched by OTTAWA HOSPITAL RESEARCH INSTITUTE · Dec 22, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the effects of hormonal therapy, specifically androgen deprivation therapy (ADT), on preventing prostate cancer from coming back after surgery. Prostate cancer is common in men, and many patients undergo surgery called radical prostatectomy to remove the cancer. However, about 40% of these patients may experience a recurrence of cancer afterward. This trial is testing whether giving ADT for one year right after surgery can help reduce the chances of the cancer returning for men who are at high risk of recurrence.

To participate in this trial, men aged 65 to 74 who have had surgery and have a very low level of a specific blood marker (PSA) are eligible, as long as they are predicted to have a 25% or greater chance of recurrence within five years. Participants will receive the ADT for one year and will be closely monitored for their health and cancer outcomes. It’s important to note that men who have already received ADT, have cancer spread to lymph nodes, or have allergies to ADT are not eligible. This trial aims to provide valuable information that could help improve treatment for prostate cancer patients in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. undetectable PSA (\<0.02 ng/ml) within 16 weeks post-operative;
• • 2. ≥25% predicted risk of PSA recurrence within 5 years of surgery (based on the Kattan nomogram)
• Exclusion Criteria:
• • 1. Unwilling to receive ADT;
• • 2. previously received ADT;
• • 3. lymph node metastases
• • 4. allergy to any form of ADT